Ieq Capital LLC Makes New $2.27 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Ieq Capital LLC purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, HoldingsChannel.com reports. The fund purchased 227,421 shares of the biotechnology company’s stock, valued at approximately $2,274,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Larson Financial Group LLC increased its position in BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $52,000. Pallas Capital Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $101,000. Focus Partners Wealth purchased a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Cantor Fitzgerald boosted their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Royal Bank Of Canada lowered their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Wedbush dropped their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Needham & Company LLC reduced their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target on the stock. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Stock Up 1.5%

NASDAQ:BCRX opened at $9.83 on Wednesday. The company has a market cap of $2.51 billion, a P/E ratio of -6.55 and a beta of 0.56. The firm’s 50 day moving average is $9.66 and its two-hundred day moving average is $9.00. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The business’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.15 EPS. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.